Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292288 | 0.88 | MEN1 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL4296733 | 0.85 | MEN1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4297014 | 0.84 | MEN1 (0.40) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4296386 | 0.84 | MEN1 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4287067 | 0.83 | MEN1 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4287151 | 0.83 | MEN1 (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL14107085 | 0.82 | MEN1 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14107088 | 0.82 | MEN1 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4744098 | 0.82 | MEN1 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14583092 | 0.81 | MEN1 (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | MEN1 4829/4885KMT2A 1440/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.